/

WVE

Wave Life Sciences, Inc.Open

3.10−0.18 −5.64%USD

NasdaqGM · as of Oct 13, 14:51 ET · 15m delay

Open

3.27

Prev close

3.28

Day range

3.083.27

52-week range

3.0821.73

Volume

1.91M0.62×

Mkt cap

609.86M

P/E ttm

—

Fwd P/E

-2.67

EPS ttm

-1.08

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−85.76%

Price Chart

Yahoo Finance · delayed

WVEOct 13, 2026O 3.27H 3.27L 3.08C 3.10−0.18 (−5.64%)Vol 1.91M

SMA 504.64
SMA 2008.22

1Y change −59.28% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

WVE Wave Life Sciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.07%
1 month: −32.57%
3 months: −49.51%
6 months: −58.12%
Year to date: −81.79%
1 year: −60.27%

Valuation & ownership

Market cap: 609.86M
Enterprise value: 199.31M
P/E (ttm): —
Forward P/E: -2.67
PEG ratio: —
Price / book: 1.32
Price / sales (ttm): 9.33
EV / EBITDA: -0.93
EPS (ttm): -1.08
EPS (forward): -1.16
Beta (5y monthly): -1.43
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 197.05M
Float: 94.30M
Short % of float: 11.62%
Short ratio (days): 5.45
Held by insiders: 15.54%
Held by institutions: 85.36%
Avg volume (3m): 3.09M
50-day average: 4.69
200-day average: 8.30
52-week change: −60.27%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 19.7
vs 50-day SMA: −33.26%
vs 200-day SMA: −62.35%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.11%
Realised vol (20d, ann.): 53.2%
From 52-week high: −85.76%
From 52-week low: +0.49%

ANR

Analyst Consensus

18 analysts

Consensus

Strong buy

1.32 on a 1 (strong buy) – 5 (sell) scale

Mean target

18.06

+483.38% implied

Low 10.00Median 14.50High 42.00

Recommendation trend

Now17 / 2 / 0
1m ago / 2 /

DES

About Wave Life Sciences, Inc.

Yahoo Finance profile

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 317
Headquarters: Cambridge, MA, United States
Website: wavelifesciences.com
Officers: Dr. Paul B. Bolno M.B.A., M.D. President, CEO & Director
Dr. Gregory L. Verdine Ph.D. Founder & Director
Mr. Kyle B. Moran CFA CFO & Principal Accounting Officer
Dr. Chandra Vargeese Ph.D. Chief Technology Officer

SEAS

Seasonality · WVE

2015–2026 · monthly returns

Strongest month Aug +16.63%Weakest month Mar −8.53%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-23.9	7.7	-48.0	-2.6	-6.8	-11.7	-5.2	-11.1	-24.5	-16.4			−81.8%
2025	-6.5	-8.6	-23.6	-4.5	-22.2	8.2	24.6	18.5	-23.8	23.5	-14.2	119.1	+37.4%
2024	-14.5	11.3	28.3	-20.1	25.4	-19.3	32.5	-13.2	42.9	67.2	10.1	-18.1	+145.0%
2023	-29.6	-14.8	3.1	-7.9	-0.8	-8.1	20.1	-0.5	32.2	-6.4	-1.3	-4.9	−27.9%
2022	-30.3	12.3	-18.7	-2.5	-28.2	132.1	-21.8	16.9	21.5	32.7	-11.5	65.1	+122.9%
2021	29.2	-7.5	-40.4	9.6	11.2	-2.6	-17.3	14.9	-22.6	-6.3	-15.0	-19.5	−60.1%
2020	-11.5	18.9	11.0	-7.4	17.3	2.3	-15.7	42.7	-32.2	-16.7	24.8	-10.8	−1.9%
2019	-11.4	12.6	-7.3	-31.7	-13.6	13.8	-17.9	7.4	-10.7	23.2	31.1	-75.8	−80.9%
2018	14.0	27.4	-21.3	10.8	4.7	-17.8	5.6	31.9	-6.2	-6.6	2.5	-12.1	+19.8%
2017	9.9	4.7	-8.6	-23.3	-10.4	-1.6	6.7	18.4	-7.4	6.0	61.4	-5.6	+34.2%
2016	-15.2	11.2	-7.8	-2.6	17.7	30.0	-6.7	29.2	30.2	-1.9	11.8	-26.5	+63.9%
2015												-1.8	−1.8%

INSD

Insider Activity · WVE

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

34.85M shares

Sells, 6 months

2.85M shares

Net shares

+32.00M

Net change in insider shares

−2314.50%

Date	Insider	Transaction	Shares	Value
Aug 11, 2026	Rawcliffe AdrianDirector	Sale at price 5.29 per share.	12.7K	$67.18K
Aug 10, 2026	Wagner Heidi LDirector	Conversion of Exercise of derivative security at price 5.97 per share.	7K	$41.79K
Aug 10, 2026	Wagner Heidi LDirector	Sale at price 6.01 per share.	7K	$42.07K
Aug 10, 2026	Takanashi KenDirector	Sale at price 6.01 per share.	3.9K	$23.22K
Aug 10, 2026	Tan Aik NaDirector	Sale at price 6.01 per share.	432	$2.60K
Mar 29, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 6.06 - 6.50 per share.	8.77M	$54.62M
Mar 22, 2026	Takanashi KenDirector	—	3.90M	—
Feb 25, 2026	Francis Christopher JohnOfficer	Conversion of Exercise of derivative security at price 3.87 - 4.75 per share.	33.2K	$141.92K
Feb 25, 2026	Francis Christopher JohnOfficer	Sale at price 15.00 - 15.09 per share.	33.2K	$499.59K
Feb 8, 2026	Moran KyleChief Financial Officer	Sale at price 13.45 per share.	3.6K	$48.26K
Feb 8, 2026	Bolno Paul B. M.D.Chief Executive Officer	Sale at price 13.45 per share.	10.5K	$140.96K
Feb 8, 2026	Vargeese ChandraOfficer	Sale at price 13.45 per share.	3.2K	$43.42K
Feb 8, 2026	Francis Christopher JohnOfficer	Sale at price 13.45 per share.	1.9K	$25.33K
Feb 4, 2026	Francis Christopher JohnOfficer	—	38.8K	—
Feb 4, 2026	Moran KyleChief Financial Officer	—	45.6K	—
Feb 4, 2026	Bolno Paul B. M.D.Chief Executive Officer	—	165K	—
Feb 4, 2026	Vargeese ChandraOfficer	—	45.6K	—
Jan 1, 2026	Francis Christopher JohnOfficer	Conversion of Exercise of derivative security at price 3.14 per share.	9.4K	$29.44K
Jan 1, 2026	Francis Christopher JohnOfficer	Sale at price 15.92 - 16.70 per share.	9.4K	$150.26K
Dec 10, 2025	Gsk PlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 19.00 per share.	1.47M	$27.93M

13F

Investors Holding WVE

latest 13F filings of 29 followed managers

Investors holding WVE
Investor	Value	Of portfolio	Shares	Change	Quarter
Maverick Capital · Lee Ainslie	$59.7M	0.53%	10.28M	+1.1%	Q2 2026
Renaissance Technologies	$9.9M	0.01%	1.70M	+185%	Q2 2026
Duquesne Family Office · Stanley Druckenmiller	$1.0M	0.02%	173.00K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

WVE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

WVE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Wave Life Sciences, Inc.

Seasonality · WVE

Insider Activity · WVE

Congress Trades · WVE

Investors Holding WVE

Investors Holding WVE

Congress Trades · WVE

Insider Activity · WVE

Seasonality · WVE

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Wave Life Sciences, Inc.

Financial Snapshot

Earnings & Dividends

News